Good morning, you're tuned in to Markets Desk.
A major pharmaceutical partnership is nursing a severe wound today after a closely watched Phase Three heart disease trial ended in failure. The two companies behind the drug saw roughly twenty-seven billion dollars in combined market value erased in a single session, a stark reminder that late-stage clinical risk never fully prices itself in until results land.
Shifting to capital markets, SK Hynix is setting up what could be a historic moment on the Nasdaq. Friday's equity offering is shaping up to be the second-largest ever, trailing only SpaceX's raise. That's a remarkable signal of investor appetite for memory chip exposure at a moment when AI infrastructure demand continues to drive semiconductor valuations higher.
And on the banking side, a wave of analyst downgrades is putting pressure on the large-cap financials ahead of second-quarter earnings. Oppenheimer's view is that valuations are now fairly priced, which on Wall Street is essentially a warning. When banks are priced for perfection, any guidance miss or net interest margin softness can create an outsized move to the downside. Watch the tape closely as earnings season opens.
That's the tape. Markets Desk, signing off the floor.
